212 related articles for article (PubMed ID: 19052742)
21. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
22. [Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma].
Robert C; Mateus C
Med Sci (Paris); 2011 Oct; 27(10):850-8. PubMed ID: 22027422
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for malignant melanoma.
Zeiser R; Schnitzler M; Andrlova H; Hellige T; Meiss F
Curr Stem Cell Res Ther; 2012 May; 7(3):217-28. PubMed ID: 22329580
[TBL] [Abstract][Full Text] [Related]
24. Introduction. Immune-modulating antibodies.
Weber J
Oncologist; 2008; 13 Suppl 4():1. PubMed ID: 19001144
[No Abstract] [Full Text] [Related]
25. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.
Minor DR; Chin K; Kashani-Sabet M
Cancer Biother Radiopharm; 2009 Jun; 24(3):321-5. PubMed ID: 19538054
[TBL] [Abstract][Full Text] [Related]
26. Recent advances using anti-CTLA-4 for the treatment of melanoma.
Sarnaik AA; Weber JS
Cancer J; 2009; 15(3):169-73. PubMed ID: 19556898
[TBL] [Abstract][Full Text] [Related]
27. Ipilimumab: controversies in its development, utility and autoimmune adverse events.
Weber J
Cancer Immunol Immunother; 2009 May; 58(5):823-30. PubMed ID: 19198837
[TBL] [Abstract][Full Text] [Related]
28. A case report of orbital inflammatory syndrome secondary to ipilimumab.
Henderson AD; Thomas DA
Ophthalmic Plast Reconstr Surg; 2015; 31(3):e68-70. PubMed ID: 24814274
[TBL] [Abstract][Full Text] [Related]
29. Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.
Lens M; Testori A; Ferucci PF
Curr Top Med Chem; 2012; 12(1):61-6. PubMed ID: 22196270
[TBL] [Abstract][Full Text] [Related]
30. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
Hodi FS; Butler M; Oble DA; Seiden MV; Haluska FG; Kruse A; Macrae S; Nelson M; Canning C; Lowy I; Korman A; Lautz D; Russell S; Jaklitsch MT; Ramaiya N; Chen TC; Neuberg D; Allison JP; Mihm MC; Dranoff G
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3005-10. PubMed ID: 18287062
[TBL] [Abstract][Full Text] [Related]
31. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
O'Day SJ; Hamid O; Urba WJ
Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
[TBL] [Abstract][Full Text] [Related]
32. Ipilimumab.
Sondak VK; Smalley KS; Kudchadkar R; Grippon S; Kirkpatrick P
Nat Rev Drug Discov; 2011 Jun; 10(6):411-2. PubMed ID: 21629286
[No Abstract] [Full Text] [Related]
33. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
Ansell SM; Hurvitz SA; Koenig PA; LaPlant BR; Kabat BF; Fernando D; Habermann TM; Inwards DJ; Verma M; Yamada R; Erlichman C; Lowy I; Timmerman JM
Clin Cancer Res; 2009 Oct; 15(20):6446-53. PubMed ID: 19808874
[TBL] [Abstract][Full Text] [Related]
34. Delayed dermatologic hypersensitivity reaction secondary to ipilimumab.
Ludlow SP; Kay N
J Immunother; 2015 May; 38(4):165-6. PubMed ID: 25839442
[TBL] [Abstract][Full Text] [Related]
35. Ipilimumab for advanced melanoma: let's not throw caution to the winds.
Lowe M; Delman KA
Oncology (Williston Park); 2010 Dec; 24(14):1296, 1299. PubMed ID: 21294473
[No Abstract] [Full Text] [Related]
36. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
Weber J
Oncologist; 2007 Jul; 12(7):864-72. PubMed ID: 17673617
[TBL] [Abstract][Full Text] [Related]
37. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
[TBL] [Abstract][Full Text] [Related]
38. Refractory idiopathic pure red cell aplasia complicated by immune thrombocytopenia successfully treated with subcutaneous alemtuzumab.
Pham DC; Guthrie TH; Villas BH; Salazar E
Am J Hematol; 2008 Jul; 83(7):603. PubMed ID: 18273896
[No Abstract] [Full Text] [Related]
39. Betting on immunotherapy for melanoma.
Sznol M
Curr Oncol Rep; 2009 Sep; 11(5):397-404. PubMed ID: 19679015
[TBL] [Abstract][Full Text] [Related]
40. Newer developments in the immunotherapy of malignant melanoma.
Maslin B; Alexandrescu DT; Ichim TE; Dasanu CA
J Oncol Pharm Pract; 2014 Feb; 20(1):3-10. PubMed ID: 23435643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
